Advances in Immunotherapy of Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Dongying, Yu, Yongchao, Mei, Qingyun, Wang, Ziwei, Li, Xiaojiang, Jia, Yingjie, Kong, Fanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374846/
https://www.ncbi.nlm.nih.gov/pubmed/34429612
http://dx.doi.org/10.2147/OTT.S317434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374846/
https://www.ncbi.nlm.nih.gov/pubmed/34429612
http://dx.doi.org/10.2147/OTT.S317434

Ejemplares similares